PV25 Speakers

Subject to change.

 

 

image

Travis Wold

CEO, Imagenomix Corp

Travis Wold is the CEO of Imagenomix Corp., an NYU spinout advancing cancer diagnostics with artificial intelligence. He leads the company’s mission to detect cancer-causing mutations directly from H&E pathology slides, creating faster and more accurate insights for physicians, patients, and pharmaceutical partners.

Under his leadership, Imagenomix secured its first pharmaceutical client and is developing a pipeline of novel, patented products scheduled for launch in 2026 and 2027. These innovations are designed to transform precision oncology and real-time diagnostics across both clinical and pharmaceutical settings.

With a strong background in medical technology ventures, Travis is known for building teams that unite world-class pathologists, oncologists, and AI experts. He continues to guide Imagenomix toward reshaping the future of cancer care by combining breakthrough science with practical clinical impact.

 

 

SESSIONS

PathPresenter: Into the PathoVerse: An Integrated Platform for Smarter Pathology
   Sun, Oct 5
   12:15PM - 01:15PM PT
  Seaport Ballroom G

Pathology has entered a bold new frontier: the PathoVerse. In this emerging universe, pathologists and institutions are using new technologies and methods that are redefining the delivery of precision medicine, with pathology at its core.

 

Yet every new universe presents challenges. The PathoVerse demands new skills, new approaches, and adaptability. Navigating it successfully requires more than technology – it requires a trusted guide.

 

In this session, with insight from PathPresenter partners across storage, compute, scanners, and AI, we’ll chart the course for thriving in the PathoVerse, from identifying and capturing ROI to unlocking AI’s full potential. 

 

Join us to discover how to make the journey through the PathoVerse a successful one.

Chat bot